![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo](/content/dam/novonordisk/novomedlink/logos/bleeding-disorders/esperoct.svg)
Extended half-life for fewer infusionsa
With Esperoct®, your hemophilia A patients may need up to 50% fewer infusions per yeara compared to standard half-life (SHL) dosing regimens.
a50% fewer for adults and adolescents if previously dosed every other day; 40% fewer if previously dosed 3x/week.
Extended half-life for fewer infusionsa
With Esperoct®, your hemophilia A patients may need up to 50% fewer infusions per yeara compared to standard half-life (SHL) dosing regimens.
a50% fewer for adults and adolescents if previously dosed every other day; 40% fewer if previously dosed 3x/week.
Extended half-life for fewer infusionsa
With Esperoct®, your hemophilia A patients may need up to 50% fewer infusions per yeara compared to standard half-life (SHL) dosing regimens.
a50% fewer for adults and adolescents if previously dosed every other day; 40% fewer if previously dosed 3x/week.
Extended half-life for fewer infusionsa
With Esperoct®, your hemophilia A patients may need up to 50% fewer infusions per yeara compared to standard half-life (SHL) dosing regimens.
a50% fewer for adults and adolescents if previously dosed every other day; 40% fewer if previously dosed 3x/week.
Extended half-life for fewer infusionsa
With Esperoct®, your hemophilia A patients may need up to 50% fewer infusions per yeara compared to standard half-life (SHL) dosing regimens.
a50% fewer for adults and adolescents if previously dosed every other day; 40% fewer if previously dosed 3x/week.
Extending half-life through PEGylation
Esperoct® extends half-life by conjugating a 40-kDa polyethylene glycol residue to an O-linked glycan in the truncated B-domain of rFVIII.1-3
Esperoct® is a recombinant factor VIII treatment
Esperoct® is made without human blood, plasma, or proteins. According to MASAC, recombinant factor VIII products are a recommended treatment of choice for patients with hemophilia A.4,a
aA possible exception is for newly diagnosed patients, which should be further discussed with the healthcare provider. Please refer to MASAC for full recommendations.
Starting patients on Esperoct®
Novo Nordisk provides resources to help your patient get started on Esperoct®.
Esperoct® was shown to provide effective prophylaxis.5
Selected Important Safety Information for Esperoct®
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
Indications and Usage
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes
- Esperoct® is not indicated for the treatment of von Willebrand disease
Important Safety Information
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
- Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
- The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions
Please click here for Esperoct® Prescribing Information.
References:
- Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670-678.
- Esperoct® Summary of Product Characteristics, Novo Nordisk, 2019.
- Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(02):252-261.
- National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.
- Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.